And the researchers behind the semaglutide trial above call weight reduction the main effect on the skeleton
In this blog post we examine the overall market context from the top-selling drugs of 2025 H1 to the surge of dealmaking in obesity therapeutics and then drill into why Eli Lilly, with its GLP-1 pipeline and commercialization strategy, has emerged as the biggest beneficiary of this trend
their deposition causes deleterious effects on neurodegenerative diseases, diabetes, arthritis, and cell damage through involving the NF-B, MAPKs, and Keap1-Nrf2-ARE etc
Affordability The cash price for GLP-1s can be prohibitive for people who dont have insurance coverage for them
Other less common side effects include fatigue, dizziness, small increases in heart rate, and in some cases, alopecia (hair thinning)